Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
January 10, 2023 16:05 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
December 19, 2022 16:05 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
December 01, 2022 16:05 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation...
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
November 22, 2022 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
November 21, 2022 16:05 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation...
Avadel Pharmaceuticals Announces Favorable Ruling on Motion to Delist REMS Patent from FDA’s Orange Book
November 18, 2022 14:45 ET
|
Avadel Pharmaceuticals plc
- Delisting of REMS Patent sets path to potentially accelerate final approval by FDA DUBLIN, Ireland, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a...
Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference
November 10, 2022 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 09, 2022 07:30 ET
|
Avadel Pharmaceuticals plc
LUMRYZ™ granted tentative approval on July 18, confirming its safety profile and clinical efficacyFinal approval decision of LUMRYZ expected by June 2023; advancing strategy to potentially accelerate...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
November 07, 2022 16:05 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation...
Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9
November 02, 2022 16:05 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...